Positive OS results with a clinically relevant benefit of ribociclib plus NSAI are demonstrated, consistent with the increasing reduction in recurrence risk, and reinforce the benefit of ribociclib plus NSAI in the adjuvant setting across the broad NATALEE-eligible population.
D. Slamon, G. Hortobagyi, D. Stroyakovskiy et al.· Annals of Oncology· 1 citation
ADCs efficacy in metastatic breast cancer was similar across age groups, though data in early-stage disease were limited, and insufficient age- and treatment-stratified toxicity reporting precludes meaningful safety assessment of ADCs in older adults with breast cancer.
Samuel Margolis, T. R. Kalbasi, Yuliya Zektser et al.· Journal of the National Canc...· 0 citations
Background In the global phase III TROPION-Breast01 study, datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) by blinded independent central review (BICR) versus investigator’s choice of chemotherapy (ICC) in patients with...
S. Wang, Q. Zhang, Z. Jiang et al.· ESMO Open· 0 citations
This large collection of MBC cfDNA data is envisioned as an invaluable resource for the design and planning of future clinical trials, and cfDNA testing is now recommended in multiple advanced malignancies, including eligibility assessment for clinical trials.
I. Leshchiner, A. Medford, J. Cha et al.· Nature Communications· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.